Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 24, 2011

Yale University Researcher and Amway Team Up for Skin Pigmentation Study

  • Yale University senior researcher John Pawelek, Ph.D., entered into an exclusive three-year agreement with Amway to investigate the biological mechanisms underlying skin pigmentation. The goals of the research are to better understand human skin pigmentation disorders including hyperpigmentation and develop therapies for the conditions.

    The agreement aims to expand on the finding of previous skin cancer research led by Dr. Pawelek, which helped identify several novel aspects of the cell biology of melanocytes, cells that synthesize the pigment melanin. Research will focus on determining whether the cell biology of melanoctyes culled from human melanoma biopsy samples is also present in experimental models including cell and tissue cultures.

    Through the partnership Amway hopes to identify new technologies to enhance the performance of its whitening products sold under its our Artistry® skincare brand, states Catherine Ehrenberger, vp, R&D and quality assurance for Amway.

    “Artistry’s goal, and mine, is to find new ways to inhibit pigmentation. We have a plan for developing products over the next several years that, for the first time, could target specific disorders," Pawelek notes.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »